Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Pyrotinib is an inhibitor of EGFR and HER2 (IC50s = 13 and 38 nM, respectively).1 It selectively inhibits the proliferation of HER2-positive BT474 breast and SKOV3 ovarian cancer cells (IC50s = 5.1 and 43 nM, respectively) over HER2-negative MDA-MB-231 breast cancer cells (IC50 = 3,500 nM). In vivo, pyrotinib (10 mg/kg per day) decreases tumor growth without affecting body weight in BT474 and SKOV3 mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur. J. Pharm. Sci. 110, 51-61 (2017).